Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2025
Reporting Period: Fourth quarter and fiscal year ended December 31, 2024
This filing serves as a notification that the Company issued a press release and investor presentations regarding its financial results for the period ended December 31, 2024. The detailed financial data is contained in the referenced exhibits (Exhibit 99.1, 99.2, and 99.3) and is not embedded directly within the text of this 8-K form.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide specific numerical values for revenue, net income, operating cash flow, profit margins, debt levels, or liquidity ratios. These metrics are disclosed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in this document.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data points or percentage changes comparing the current period to prior comparable periods. Investors must refer to the attached press release (Exhibit 99.1) for a detailed analysis of operational and financial changes.
Guidance, Outlook, and Management Commentary
- Investor Communications: On February 28, 2025, the Company released an updated investor presentation (Exhibit 99.2) and an earnings call presentation (Exhibit 99.3).
- Disclosure Channels: The Company utilizes SEC filings, its investor relations website (https://ir.recursion.com/), press releases, conference calls, and social media to communicate material information.
- Legal Status of Exhibits: The information in Items 2.02 and 7.01, including the exhibits, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2024 financial results, including revenue and cash burn rates.
- Examine Exhibit 99.2 and Exhibit 99.3 for management's updated strategic outlook and guidance.
- Verify the Company's liquidity position and runway based on the cash balance reported in the press release.
- Confirm any updates to the Company's drug development pipeline or partnership agreements mentioned in the earnings call materials.